Gender Differences in Platelet GPIIb-IIIa Activation

Nauder Faraday; Pascal J Goldschmidt-Clermont; Paul F Bray

doi:10.1055/s-0038-1656045

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 77(04): 748-754
DOI: 10.1055/s-0038-1656045

Platelets

Schattauer GmbH Stuttgart

Gender Differences in Platelet GPIIb-IIIa Activation

Authors

Nauder Faraday

The Divisions of Hematology and Cardiology, and Departments of Medicine and Anesthesiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Pascal J Goldschmidt-Clermont

The Divisions of Hematology and Cardiology, and Departments of Medicine and Anesthesiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Paul F Bray

The Divisions of Hematology and Cardiology, and Departments of Medicine and Anesthesiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract

PDF Download

Summary

Gender differences in the development of thrombotic diseases have been described in numerous clinical settings. Enhanced platelet reactivity in both sexes is associated with the development of vascular thromboses. Because activation of platelet GPIIb-IIIa receptors is a central event in thrombus formation, we examined GPIIb-IIIa function in normal male and female volunteers. Using flow cytometry, we quantitated gender differences in the number of binding sites for FITC-labeled fibrinogen (FITC-FGN) and FITC-labeled PAC-1 antibody (FITC-PAC-1). Washed platelets were incubated with either FITC-FGN or FITC-PAC-1 and activated with either ADP or thrombin receptor activating peptide (TRAP) prior to cytometric acquisition of data. The dissociation constant for FITC-FGN was the same in both sexes (approx. 1.6 x 10-⁷M), however, the number of GPIIb-IIIa receptors per platelet capable of binding fibrinogen was significantly greater in women than men in response to 20μM ADP (16,319 ± 1871 vs 9669±1994, p = 0.02), 20μM ADP (39,951 ± 4711 vs 25,948 ± 4953, p = 0.05) and 50μM TRAP (39,236 ± 3965 vs 21,848 ± 4159, p = 0.007). Similarly, the number of GPIIb-IIIa receptors capable of binding PAC-1 in response to ADP and TRAP was 50% to 80% greater in women than men. Binding experiments using specific anti-GPIIb-IIIa monoclonal antibodies (P2 and 10E5), as well as quantitative Western blotting experiments, showed no gender difference in the total number of GPIIb-IIIa molecules expressed. Analysis of data from female subgroups demonstrated an association of GPIIb-IIIa reactivity with menstrual phase. We conclude that GPIIb-IIIa receptors on platelets from premenopausal women are more “activatable” than those on platelets from young men. Variations in the serum concentrations of estrogens and/or progestins may modulate GPIIb-IIIa function.

PDF (2417 kb)

References

References
1 Puletti M, Sunseri L, Curione M, ErbaS M, Borgia C. Acute myocardial infarction: sex-related differences in prognosis. Am Heart J 1984; 108: 63-66
2 Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. In-hospital and 1-year mortality in 1,524 women after myocardial infarction Comparison with 4,315 men [see comments]. Circulation 1991; 83: 484-491
3 Loop FD, Golding LR, MacMillan JP, Cosgrove DM, Lytle BW, Sheldon WC. Coronary artery surgery in women compared with men: analyses of risks and long-term results. J Am Coll Cardiol 1983; 1: 383-390
4 Letsky E, de SwietM. Annotation. Thromboembolism in pregnancy and its management. [Review]. Br J Haematol 1984; 57: 543-552
5 Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). [Review]. N Engl J Med 1981; 305: 612-618
6 Stadel BV. Oral contraceptives and cardiovascular disease (second of two parts). [Review]. N Engl J Med 1981; 305: 672-677
7 Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 1977; 297: 1246-1249
8 The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53-59
9 Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989
10 Socol ML, Weiner CP, Louis G, Rehnberg K, Rossi EC. Platelet activation in preeclampsia. Am J Obstet Gynecol 1985; 151: 494-497
11 Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253: 355-357
12 Zahavi J, Dreyfuss F, Kalef M, Soferman N. Adenosine diphosphate-induced platelet aggregation in healthy women with and without a combined and sequential contraceptive pill. Am J Obstet Gynecol 1973; 117: 107-113
13 Yamazaki H, Motomiya T, Kikutani N, Sakakibara C, Watanabe S, Numata M, Noguchi K. Platelet aggregation during menstrual cycle and pregnancy. Thromb Res 1979; 14: 333-340
14 Kelton JG, Powers P, Julian J, Boland V, Carter CJ, Gent M, Hirsh J. Sex-related differences in platelet aggregation: influence of the hematocrit. Blood 1980; 56: 38-41
15 Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein Ilb/IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114
16 Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994; 123: 728-740
17 Finkel T, Theriot JA, Dise KR, Tomaselli GF. Goldschmidt-Clermont PJ. Dynamic actin structures stabilized by profilin. Proc Natl Acad Sci USA 1994; 91: 1510-1514
18 Klotz IM. Numbers of receptor sites from Scatchard graphs: facts and fantasies. Science 1982; 217: 1247-1249
19 Vassallo Jr R, Kieber-Emmons T, Cichowski K, Brass LF. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem 1992; 267: 6081-6085
20 McGregor JL, Brochier J, Wild F, Follea G, Trzeciak MC, James E, Decha-vanne M, McGregor L, Clemetson KJ. Monoclonal antibodies against platelet membrane glycoproteins. Characterization and effect on platelet function. Eur J Biochem 1983; 131: 427-436
21 Peerschke El, Coller BS. A murine monoclonal antibody that blocks fibrinogen binding to normal platelets also inhibits fibrinogen interactions with chymotrypsin-treated platelets. Blood 1984; 64: 59-63
22 Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980; 255: 154-161
23 Plow EF, Marguerie GA. Induction of the fibrinogen receptor on human platelets by epinephrine and the combination of epinephrine and ADP. J Biol Chem 1980; 255: 10971-10977
24 Niiya K, Hodson E, Bader R, Byers-Ward V, Koziol JA, Plow EF, Ruggeri ZM. Increased surface expression of the membrane glycoprotein Ilb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 1987; 70: 475-483
25 Elkeles RS, Hampton JR, Mitchell JR. Effect of oestrogens on human platelet behaviour. Lancet 1968; 2: 315-318
26 Lessey BA, Damjanovich L, Coutifaris C, Castelbaum A, Albelda SM, Buck CA. Integrin adhesion molecules in the human endometrium. Correlation with the normal and abnormal menstrual cycle. J Clin Invest 1992; 90: 188-195
27 Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood 1993; 82: 2693-2703
28 Goldschmidt-Clermont P, Schulman S, Bray P, Chandra N, Khan F, Grigoryev D, Kitt M, Gottdiener P, Gerstenblith G. Refining the treatment for women with unstable angina. Clin Card 1996; 19: 869-874